Literature DB >> 26699828

Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease.

Anthony Buisson1, Constance Hordonneau2, Marion Goutte3, Julien Scanzi4, Felix Goutorbe4, Thomas Klotz2, Louis Boyer2, Bruno Pereira5, Gilles Bommelaer3.   

Abstract

BACKGROUND: Diffusion-weighted magnetic resonance entero-colonography (DW-MREC) with no rectal distension and with no bowel cleansing is accurate to assess inflammatory activity in ileocolonic Crohn's disease (CD). AIM: To study DW-MREC parameters as predictors of remission (CDAI < 150 and CRP < 5mg/L) after anti-TNF induction therapy.
METHODS: Forty consecutive CD patients were prospectively and consecutively included. All the patients underwent DW-MREC with apparent diffusion coefficient (ADC) and MaRIA calculation before starting anti-TNF. Mean ADC was defined as the mean of the segmental ADC.
RESULTS: Twenty patients (50.0%) experienced remission at W12. Low mean ADC (2.05 ± 0.22 vs 1.89 ± 0.25, p = 0.03) and high total MaRIA (39.2 ± 16.6 vs 51.7 ± 18.2, p = 0.03) were predictive of remission at W12. Using a ROC curve, we determined a mean ADC of 1.96 as predictive cut-off of remission at W12 (AUC = 0.703 [0.535-0.872]) with sensitivity, specificity, positive predictive value and negative predictive value of 70.0%, 65.0%, 66.7% and 68.4%, respectively. In multivariate analysis, mean ADC < 1.96 (OR = 4.87, 95% CI [1.04-22.64]) and total MaRIA > 42.5 (OR = 5.11, 95% CI [1.03-25.37]), reflecting high inflammatory activity, were predictive of remission at week 12.
CONCLUSIONS: DW-MREC using quantitative parameters i.e. ADC, is useful in detecting and assessing inflammatory activity but also to predict efficacy of anti-TNF induction therapy in CD.
Copyright © 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-TNF; Crohn's disease; Diffusion-weighted MRI; Predictive factor

Mesh:

Substances:

Year:  2015        PMID: 26699828     DOI: 10.1016/j.dld.2015.10.019

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  Medical Therapies for Stricturing Crohn's Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure.

Authors:  Cécile Campos; Antoine Perrey; Céline Lambert; Bruno Pereira; Marion Goutte; Anne Dubois; Felix Goutorbe; Michel Dapoigny; Gilles Bommelaer; Constance Hordonneau; Anthony Buisson
Journal:  Dig Dis Sci       Date:  2017-04-11       Impact factor: 3.199

2.  Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn's disease.

Authors:  Anthony Buisson; Constance Hordonneau; Felix Goutorbe; Christophe Allimant; Marion Goutte; Maud Reymond; Bruno Pereira; Gilles Bommelaer
Journal:  J Gastroenterol       Date:  2018-08-30       Impact factor: 7.527

3.  Evaluation of ileal Crohn's disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results.

Authors:  Sonja Gordic; Octavia Bane; Shingo Kihira; Steven Peti; Stefanie Hectors; Joana Torres; Judy Cho; Jean-Frederic Colombel; Bachir Taouli
Journal:  Eur J Radiol Open       Date:  2020-01-28

4.  Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.

Authors:  Pierre Baillet; Guillaume Cadiot; Marion Goutte; Felix Goutorbe; Hedia Brixi; Christine Hoeffel; Christophe Allimant; Maud Reymond; Hélène Obritin-Guilhen; Benoit Magnin; Gilles Bommelaer; Bruno Pereira; Constance Hordonneau; Anthony Buisson
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

5.  A Systematic Review of Technical Parameters for MR of the Small Bowel in non-IBD Conditions over the Last Ten Years.

Authors:  Jingyu Lu; Ziling Zhou; John N Morelli; Hao Yu; Yan Luo; Xuemei Hu; Zhen Li; Daoyu Hu; Yaqi Shen
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

6.  Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.

Authors:  M A Cozijnsen; J N Samsom; L de Ridder
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.